Sensei Biotherapeutics (NASDAQ:SNSE) Price Target Raised to $4.00 at Oppenheimer

Sensei Biotherapeutics (NASDAQ:SNSE) had its price objective upped by Oppenheimer from $3.50 to $4.00 in a report released on Friday,Benzinga reports. The firm presently has an “outperform” rating on the stock.

Separately, HC Wainwright restated a “buy” rating and issued a $4.00 price target on shares of Sensei Biotherapeutics in a report on Friday.

Sensei Biotherapeutics Price Performance

Sensei Biotherapeutics stock opened at $0.51 on Friday. The firm has a market capitalization of $12.78 million, a price-to-earnings ratio of -0.43 and a beta of 0.16. The company’s 50 day simple moving average is $0.47 and its 200 day simple moving average is $0.49. Sensei Biotherapeutics has a fifty-two week low of $0.38 and a fifty-two week high of $1.94.

Sensei Biotherapeutics (NASDAQ:SNSE) last announced its quarterly earnings results on Friday, March 28th. The company reported ($0.27) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.27). As a group, analysts predict that Sensei Biotherapeutics will post -1.17 EPS for the current fiscal year.

Hedge Funds Weigh In On Sensei Biotherapeutics

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. National Bank of Canada FI lifted its holdings in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 355.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 45,575 shares of the company’s stock after purchasing an additional 35,575 shares during the quarter. National Bank of Canada FI owned 0.18% of Sensei Biotherapeutics worth $27,000 as of its most recent SEC filing. 10.50% of the stock is owned by institutional investors and hedge funds.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.